Related Experiment Video
Updated: Oct 2, 2025
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements
Salima Akter1,2,3, Md Ataur Rahman4,5,6, Mohammad Nazmul Hasan7
1Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 02447, Korea.
Abstract:
Aggressive and recurrent gynecological cancers are associated with worse prognosis and a lack of effective therapeutic response. Ovarian cancer (OC) patients are often diagnosed in advanced stages, when drug resistance, angiogenesis, relapse, and metastasis impact survival outcomes. Currently, surgical debulking, radiotherapy, and/or chemotherapy remain the mainstream treatment modalities; however, patients suffer unwanted side effects and drug resistance in the absence of targeted therapies. Hence, it is urgent to decipher the complex disease biology and identify potential biomarkers, which could greatly contribute to making an early diagnosis or predicting the response to specific therapies. This review aims to critically discuss the current therapeutic strategies for OC, novel drug-delivery systems, and potential biomarkers in the context of genetics and molecular research. It emphasizes how the understanding of disease biology is related to the advancement of technology, enabling the exploration of novel biomarkers that may be able to provide more accurate diagnosis and prognosis, which would effectively translate into targeted therapies, ultimately improving patients' overall survival and quality of life.
Insights
This review discusses ovarian cancer (OC) treatments, highlighting the need for better therapies. Identifying new biomarkers through advanced research can improve early diagnosis, prognosis, and targeted treatments for better patient survival.
Area of Science:
- Gynecological Oncology
- Molecular Biology
- Translational Medicine
Background:
- Aggressive and recurrent gynecological cancers, particularly ovarian cancer (OC), present poor prognoses due to advanced stage diagnosis, drug resistance, angiogenesis, relapse, and metastasis.
- Current treatments like surgery, radiotherapy, and chemotherapy offer limited efficacy and significant side effects, lacking targeted therapeutic options.
Purpose of the Study:
- To critically review current therapeutic strategies for ovarian cancer (OC).
- To explore novel drug-delivery systems and potential biomarkers for OC.
- To emphasize the link between understanding OC biology, technological advancements, and the development of targeted therapies.
Main Methods:
- Literature review of current therapeutic strategies for OC.
- Analysis of genetic and molecular research for potential biomarkers.
- Discussion of novel drug-delivery systems and their application in OC treatment.
Main Results:
- Current OC treatments face challenges with efficacy and side effects.
- Advanced understanding of OC biology is crucial for identifying novel biomarkers.
- Technological advancements facilitate the discovery of biomarkers for improved diagnosis and prognosis.
Conclusions:
- There is an urgent need for novel therapeutic strategies and targeted therapies for ovarian cancer.
- Biomarker discovery through genetic and molecular research is key to improving early diagnosis and patient prognosis.
- Integrating biological insights with technological advancements can lead to improved targeted therapies, enhancing patient survival and quality of life.
More Related Videos
08:55Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...